secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-08-04T11:36:13+00:00
Accession:  0001326110-26-000077
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth
--------------------------------------------------------------------------------

- Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.
- Cash and marketable securities $357.4M as of June 30, 2026; adjusted net loss improved to $81.0M from $89.9M YoY.
- FDA accepted sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA Jan 6, 2027.
- UAE granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC.
- Exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG in NMIBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/0001326110-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer